Investigations into the Klebsiella aerogenes pentitol operons using specialised transducing phages lambdaprbt and lambdaprbt dal.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M S Neuberger.
Explore the source record for details and available documents.
Specific chromosome translocations have been observed in transformed cell lines of both man and mouse and may be implicated in the origin or maintenance of malignancy. In mouse plasmacytomas, translocations have been identified that bring the immunoglobulin alpha heavy-chain gene (C alpha, normally located on chromosome 12) into proximity with c-myc (normally located on chromosome 15), c-myc being the mouse cellular homologue of the avian myelocytomatosis virus transforming gene (v-myc). Here we identify a DNA rearrangement in a mouse hybridoma that has brought c-myc close to C gamma 2b and show that this rearrangement occurred by reciprocal chromosome translocation, as recombinant clones were isolated from the same cell line in which a rearranged variable-region (VH) gene has been brought close to 5' c-myc sequences. The translocation has resulted in the net loss of 7 base pairs (bp) of chromosome 15 sequence as well as in the presence of an additional base of unknown provenance. This reciprocal translocation was analysed in DNA from a mouse hybridoma cell line but is shown to be characteristic of the X63Ag8 myeloma parent.
The introduction into lymphocytes of immunoglobulin-gene DNA that has been manipulated in vitro allows the production of novel antibodies. In this way, cell lines have been established that secrete hapten-specific antibodies in which the Fc portion has been replaced either with an active enzyme moiety or with polypeptide displaying c-myc antigenic determinants.
Immunoglobulin E (IgE) has a central role in allergic reactions although it rarely exceeds 5 micrograms ml-1 even in the serum of severely allergic individuals. Both mast cells and basophils possess receptors which bind the Fc portion of IgE with high affinity; crosslinking of membrane-bound IgE by allergen results in degranulation of the cell and release of a variety of pharmacologically active mediator including histamine. Myeloma IgE has been successfully used to block the skin sensitizing activity of allergic sera; however, human myeloma IgE is clearly in limited supply. The emergence of techniques allowing the stable introduction of immunoglobulin gene DNA into myeloma cells has allowed us to construct a mouse cell line that secretes a chimaeric IgE, lambda 1 antibody whose heavy chain is composed of a human C epsilon constant region fused to a mouse variable (VH) region. This chimaeric IgE is specific for the hapten 4-hydroxy-3-nitro-phenacetyl (NP) and can, when crosslinked by antigen, trigger the degranulation of human basophils. When not crosslinked, however, the chimaeric IgE can prevent the passive sensitization of these cells by sera from allergic subjects.
The variable domains of an antibody consist of a beta-sheet framework with hypervariable regions (or complementarity-determining regions--CDRs) which fashion the antigen-binding site. Here we attempted to determine whether the antigen-binding site could be transplanted from one framework to another by grafting the CDRs. We substituted the CDRs from the heavy-chain variable region of mouse antibody B1-8, which binds the hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid; KNP-cap = 1.2 microM), for the corresponding CDRs of a human myeloma protein. We report that in combination with the B1-8 mouse light chain, the new antibody has acquired the hapten affinity of the B1-8 antibody (KNP-cap = 1.9 microM). Such 'CDR replacement' may offer a means of constructing human monoclonal antibodies from the corresponding mouse monoclonal antibodies.
The physiological mechanism for producing antigen-specific antibodies is based on a two-phase neo-Darwinian process: the first phase consists of diversity generation (formation of the repertoire), and the second phase is antigen-mediated selection. In this article, we consider how the natural immunoglobulin gene-diversification processes can be exploited both in vivo and in vitro in order to allow the generation of novel antibody (and heterologous protein) repertoires.